X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Non-Vaccine mRNA Therapeutics To Earn $2 Billion By 2028

Content Team by Content Team
5th December 2022
in News, Research & Development
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

A recent analysis from GlobalData estimates that by 2028, the approval of pipeline drugs will earn over $2 billion from five marketed messenger RNA (mRNA) non-vaccine products.

The analytics firm claimed that despite the fact that there are currently no mRNA non-vaccine therapeutics on the market, this factoid was derived from the anticipated combined revenue from the development of investigational cancer and rare genetic disease therapies by Ultragenyx, Moderna, Omega Therapeutics, and BioNTech.

According to GlobalData, if Ultragenyx’s OTX-2002, which has the potential to be the first programmable epigenetic drug, is developed successfully, it might produce $1.6 billion by 2028.

Based on the research, the laws governing mRNA therapies are concentrated on enhancing patient access and boosting drug reviews for medications that enhance critical disease treatment, detection, or prevention. The European Union (EU) adopted the priority medicines (PRIME) scheme in 2016 to quicken the regulatory procedure for advanced medical treatment products (ATMPS). Due to the effectiveness of mRNA vaccinations in treating the virus, there has been an increase in interest in mRNA treatments since the COVID-19 pandemic, according to GlobalData.

mRNA treatments can act on sites that have historically been undruggable for small compounds and can give individualised therapy by treating specific protein deficits in a patient’s body, said Pharmaceutical Analyst at GlobalData, Sarah Bundra.

According to the study, these medicines are a particularly attractive therapeutic choice for individuals with uncommon genetic illnesses brought on by genetic abnormalities since they can swiftly replace any missing or defective proteins.

Obstacles to mRNA therapies

Due to the demand for high-quality and extremely pure mRNA, high cost and manufacturing scalability are major obstacles to mRNA therapies reaching the market. To verify the safety, effectiveness, and quality of mRNA therapies during large-scale manufacturing, reliable analytical methodologies are required.

Delivery of mRNA in the body requires to be maximized, as mRNA molecules are vulnerable to breakdown by ribonucleases, Bundra wrote in his conclusion. This is a normal mechanism by which the body controls gene expression, but it has limitations on the in vivo effectiveness of mRNA therapies. Additionally, mRNA introduction bears the danger of immune system activation, which needs to be minimised in situations where the patient may suffer negative consequences from doing so, notably when coping with non-immunotherapeutic causes.

Previous Post

Redesigning The Human Medicines Directive And Regulation

Next Post

Launch of The First Pipeline Assessment By Vaccines Europe

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

Launch of The First Pipeline Assessment By Vaccines Europe

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In